Physician

Mabel A Mardones, M.D.

According to 2025 Medicare claims, Mabel Mardones, M.D. (NPI: 1134446461) practices hematology/oncology in the Denver-Aurora-Centennial, CO market, with the plurality of this provider's patient population coming from Arapahoe, CO. This provider's primary affiliated billing organization is ROCKY MOUNTAIN CANCER CENTERS LLP (NPI: 1518941186; TIN: 841457488) and primary practice location at 80124-5521. Mardones is affiliated with the CoreHealth Alliance LLC (ACO ID: A5645), participating under the MSSP model.

Mardones' data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 707 traditional Medicare patients, billed 126,114 HCPCS/CPT codes, and received $3,074,241 in Medicare payments. The top billing code was 86300 (Immunologic analysis for detection of tumor antigen, quantitative; ca 15-3). Part D data shows 1,144 prescription claims across 257 beneficiaries totaling $734,348 in drug costs, led by Kisqali (Ribociclib Succinate). 2022 DME data shows 11 claims. Open Payments data shows 212 records totaling $648,669. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved sharply higher in recent years, from $1,590 to $3,074,241. Similarly, Part D prescription costs have risen steadily, from $16,436 to $734,348. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	17	18	$1,590
2016	163	23,124	$294,955
2017	407	60,314	$890,857
2018	531	64,143	$1,019,607
2019	637	84,971	$1,704,245
2020	572	76,078	$1,662,515
2021	669	104,980	$2,338,369
2022	646	109,409	$2,477,365
2023	580	81,869	$1,838,151
2024	707	126,114	$3,074,241

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	35	61	$16,436
2016	42	86	$3,495
2017	127	601	$567,723
2018	156	679	$915,990
2019	254	1,184	$763,131
2020	212	877	$504,410
2021	218	1,101	$613,534
2022	259	1,289	$984,200
2023	243	1,034	$610,679
2024	257	1,144	$734,348

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	75	$6,072
2020	N/R	N/R	N/R
2021	N/R	N/R	N/R
2022	N/R	11	$553
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
86300	Immunologic analysis for detection of tumor antigen, quantitative; ca 15-3	315	622	$20
82378	Carcinoembryonic antigen (cea) protein level	315	623	$19
80053	Blood test, comprehensive group of blood chemicals	283	654	$10
36415	Insertion of needle into vein for collection of blood sample	303	569	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	316	771	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Kisqali	Ribociclib Succinate	17	476	$298,939
Ibrance	Palbociclib	16	447	$263,288
Xarelto	Rivaroxaban	19	1,161	$22,604
Eliquis	Apixaban	17	510	$9,923
Exemestane	Exemestane	54	2,940	$9,149

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	17	$10,172	Novartis Pharmaceuticals Corporation
Research Payments	Reported research-related payment or transfer-of-value amount.	195	$638,497	Genentech, Inc.
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Mabel A. Mardones, M.D.?

Tedicare shows public-source Medicare data for Mabel A. Mardones, M.D. (NPI 1134446461), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Mabel A. Mardones, M.D. have ACO affiliation data?

Mabel A. Mardones, M.D. is shown with ACO affiliation data for CoreHealth Alliance LLC (MSSP, ACO ID A5645).

What billing organization is linked to Mabel A. Mardones, M.D.?

Mabel A. Mardones, M.D. is linked to ROCKY MOUNTAIN CANCER CENTERS LLP (billing NPI 1518941186) in the available physician profile data.

Does Mabel A. Mardones, M.D. have Open Payments data?

Mabel A. Mardones, M.D. has 212 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.